|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.10.25 - 12:03
|
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum (Business Wire)
|
|
|
Med Tech segment delivers fourth consecutive quarter of over 20% revenue growth
Reported Adjusted EBITDA of $2.2 million compared to ($0.2) million in the prior year
Continues to expect to be cash flow positive for the full fiscal year 2026
Raised full year FY 2026 guidance for net sales, Med Tech net sales growth, Adjusted EBITDA and Adjusted EPS
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025.
Fiscal Year 2026 First Quarter Highlights
Quarter Ended
August 31, 2025
Pro Forma* YoY Growth
Net Sales
$75.7 million
12.2%
Med Tech Net Sales
$35.3 million
26.1%
Med Device Net Sales
$40.4 million
2.3%
GAAP gross margin of 55.3%
GAAP loss per share of $0.26
Adjusted loss per share of ...
|
|
|
|
|
18.09.25 - 14:03
|
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025 (Business Wire)
|
|
|
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Thursday, October 09, 2025 at 11:59 PM ET. To hear this recording, dial...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.07.25 - 12:36
|
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth (Business Wire)
|
|
|
Med Tech franchise delivers third consecutive quarter of over 20% revenue growth
Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025
Drove $16.2 million of free cash flow in the quarter as a result of strong topline growth and operational efficiency effortsLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2025, which ended May 31, 2025.
Fiscal Year 2025 Fourth Quarter Highlights
Quarter Ended
May 31, 2025
Pro Forma* YoY Growth
Pro Forma* Net Sales
$80.2 million
12.7%
Med Tech Net Sales
$35.8 million
22.0%
Med Device Net Sales
$44.4 million
6.2%
GAAP gross margin of 52.7% which was inclusive of a $1.6 million, or 204 basis point, tariff-driven Co...
|
|
|
|
|
07.07.25 - 14:06
|
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025 (Business Wire)
|
|
|
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2025 before the market open on Tuesday, July 15, 2025. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Tuesday, July 15, 2025 at 11:59 PM ET. To hear this recording, dial 1-84...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
